All In Biotech

Drug Trial Radar · NCT06285409

Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium

Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Apr 4, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery. An uncontracted uterine state is called "uterine atony", which can lead to an excessive amount of post-delivery bleeding. Carbetocin is an uterotonic drug that works well to prevent post-delivery bleeding. In some cases, carbetocin is not enough to contract the uterus, and ongoing bleeding continues. When that happens, there are other uterotonic medications that can be used. In this study, we aim to find which uterotonic drug, amongst those available (oxytocin, carbetocin, ergometrine or carboprost), is more effective to lower the risk of post-delivery bleeding once carbetocin has already been administered. This study will be done by using a very small sample of uterine tissue, taken from the incision site, following delivery by cesarean section. The sample is taken to the laboratory and will be exposed to carbetocin followed by other uterotonic drugs. The information obtained from this study will help modify the treatment for uterine atony and post-delivery bleeding to lower the risk further.

Conditions

  • Postpartum Hemorrhage

Interventions

  • CarbetocinDrug

    Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).

  • OxytocinDrug

    Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.

  • CarbetocinDrug

    Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M

  • OxytocinDrug

    Increasing concentrations of oxytocin from 10-10 M to 10-5 M

  • ErgonovineDrug

    Increasing concentrations of ergometrine from 10-10 M to 10-5 M

  • CarboprostDrug

    Increasing concentrations of carboprost from 10-10 M to 10-5 M

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Motility indexTime frame: 4 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Hospital

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.